Materials and METHODS: HUVEC were treated with TNF-alpha (10 ng/mL) in either the absence or presence of carvedilol. The levels of intracellular reactive oxygen species (ROS) were examined using a fluorescent dye DCFH-DA, with the adhesion of U-937 monocyte to the HUVEC. Nuclear factor kappa B (NF-kappaB) activation was determined by NF-kappaB p65 translocation to the nucleus using Western blotting and immunocytochemistry. The expressions of NF-kappaB dependent pro-inflammatory molecules, i.e., vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1 and interleukin (IL)-8, were measured by RT-PCR and ELISA. Bcl-2 and phosphorylation of c-Jun N-terminal protein kinase (JNK) were measured using Western blotting.

RESULTS: TNF-alpha treatment increased the activation of NF-kappaB, suppressed Bcl-2, and increased the phosphorylation of JNK, the ROS level and the adhesion of U-937. The levels of mRNA and protein expressions of VCAM-1, ICAM-1, MCP-1 and IL-8 were up-regulated by TNF-alpha. Carvedilol inhibited the phosphorylation of JNK, ROS formation and the adhesion of U-937 monocyte. In addition, carvedilol reduced the production of VCAM-1, ICAM-1, MCP-1 and IL-8 at the mRNA and protein levels, via the suppression of NF-kappaB activation.

CONCLUSION: These results suggested that the anti-inflammatory effects of carvedilol on TNF-alpha stimulated endothelial cells could be explained by its ROS-scavenging and NF-kappaB inactivation properties.